Search Within

Andrew D Zelenetz

Formats
  1. Meeting Abstract (461)
  2. Journal Article (288)
  3. Research Letter (14)
  4. Book Section (7)
  5. Guidelines (5)
  6. Conference Paper (3)
  7. Correspondence (3)
  8. Editorial (3)
  9. Review (1)
Groups
  1. Center for Hematologic Malignancies (785)
  2. Department of Medicine (785)
  3. Hematologic Malignancies, Division of (785)
  4. Lymphoma (785)
  5. Survivorship Research (234)
  6. Population Sciences Research Program (189)

More Groups

People
  1. Craig Moskowitz (207)
  2. Ariela Noy (188)
  3. Paul Hamlin (187)
  4. Steven Horwitz (169)
  5. David Straus (163)
  6. Maria Palomba (143)

More People

Years
  1. 2025 (8)
  2. 2024 (31)
  3. 2023 (43)
  4. 2022 (30)
  5. 2021 (29)
  6. 2020 (32)

More Years

Publications
  1. Blood (329)
  2. Journal of Clinical Oncology (83)
  3. Journal of the National Comprehensive Cancer Network (35)
  4. British Journal of Haematology (34)
  5. Leukemia and Lymphoma (31)
  6. Annals of Oncology (26)

More Publications

Publishers
  1. American Society of Hematology (341)
  2. American Society of Clinical Oncology (85)
  3. John Wiley & Sons (41)
  4. Harborside Press (35)
  5. Elsevier Inc. (31)
  6. Oxford University Press (31)

More Publishers

Results (785)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinical outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg type treated in the rituximab era: Long-term follow-up of a single-center experience
    Meeting Abstract

    Falchi, L.; Qiu, A.; Ewalt, M. D.; Batlevi, C. L.; Caron, P. C.; Hamlin, P. A.; Hamilton, A.; Horwitz, S. M.; Joffe, E.; Khan, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Impact of choice of platinum-based salvage therapy on CNS relapse in patients with relapsed or refractory diffuse large B-cell lymphoma
    Meeting Abstract

    Buege, M. J.; Dao, P.; Dematteo, R. G.; LeVoir, A.; Pak, T.; Batlevi, C. L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • NCCN Guidelines® Insights: B-cell lymphomas, version 5.2021: Featured updates to the NCCN Guidelines
    Guidelines

    Zelenetz, A. D.; Gordon, L. I.; Chang, J. E.; Christian, B.; Abramson, J. S.; Advani, R. H.; Bartlett, N. L.; Budde, L. E.; Caimi, P. F.; De Vos, S.; more...
    Journal of the National Comprehensive Cancer Network (2021)

    Fulltext@MSK | Save
  • Initial results of the combination of PI3Kδ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies
    Meeting Abstract

    Soumerai, J. D.; Jagadeesh, D.; Salman, H. S.; Lossos, I. S.; Asch, A. S.; Reddy, N.; Kenkre, V. P.; Pagel, J. M.; Persky, D. O.; Awan, F. T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy and safety of the PI3K delta inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24)
    Meeting Abstract

    Pagel, J. M.; Reddy, N.; Jagadeesh, D.; Stathis, A.; Asch, A. S.; Salman, H. S.; Kenkre, V. P.; Soumerai, J. D.; Llorin-Sangalang, J.; Gorbatchevsky, I.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma
    Meeting Abstract

    Khan, N.; Khimani, F.; Shustov, A. R.; Shadman, M.; Ruan, J.; Moskowitz, A. J.; Straus, D. J.; Kumar, A.; Sauter, C. S.; Zelenetz, A. D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Zanubrutinib, obinutuzumab, and venetoclax with minimal residual disease-driven discontinuation in previously untreated patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: A multicentre, single-arm, phase 2 trial
    Journal Article

    Soumerai, J. D.; Mato, A. R.; Dogan, A.; Seshan, V. E.; Joffe, E.; Flaherty, K.; Carter, J.; Hochberg, E.; Barnes, J. A.; Hamilton, A. M.; more...
    The Lancet Haematology (2021)

    Fulltext@MSK | Save
  • Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: Is 4 Gy suitable for curable patients?
    Journal Article

    Imber, B. S.; Chau, K. W.; Lee, J.; Lee, J.; Casey, D. L.; Yang, J. C.; Wijentunga, N. A.; Shepherd, A.; Hajj, C.; Qi, S.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
    Journal Article

    Mehta-Shah, N.; Lunning, M. A.; Moskowitz, A. J.; Boruchov, A. M.; Ruan, J.; Lynch, P.; Hamlin, P. A.; Leonard, J.; Matasar, M. J.; Myskowski, P. L.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save